BOC-nitro-L-arginine, formally N^α-tert-butoxycarbonyl-N^ω-nitro-L-arginine (CAS 2188-18-3, molecular weight 319.31 g/mol, molecular formula C₁₁H₂₁N₅O₆), is a protected L-arginine derivative supplied as a white to off-white crystalline powder for solid-phase peptide synthesis operating under Boc/benzyl protection logic. The tert-butoxycarbonyl group masks the α-amino terminus, while the nitro group on the guanidino side chain prevents acylation or branching at the ω-nitrogen during chain elongation. In a routine Boc cycle, reagent-grade trifluoroacetic acid removes the α-amino Boc group without disturbing the nitro-guanidino function; final guanidino liberation is then accomplished by catalytic hydrogenation, liquid hydrogen fluoride/anisole, or process-specific reductive acidic conditions, depending on the peptide sequence and resin linker. The material is supplied as a single peptide-synthesis grade, and catalogue descriptors may include Boc-Arg(NO₂)-OH or Boc-N-nitro-L-arginine. No alternative salt forms or polymer-bound grades are widely distributed. Packaging is amber glass or double polyethylene sealed under inert gas, and controlled storage is required to prevent premature loss of the Boc group or moisture uptake.

Release Specification, Identity Testing, and Reference-Standard Alignment

Release acceptance for peptide-synthesis-grade lots is based on identity, chromatographic purity, residual water, residual solvent, and residue on ignition rather than a single descriptive label. Table 1 lists typical parameters that appear on certificate-of-analysis documents; exact acceptance limits are supplier-specific and should not replace the batch certificate.

For regulated peptide drug-substance programmes, the chromatographic purity method must separate the L-arginine derivative from epimeric or deprotected contaminants. Conventional reversed-phase columns with 5 µm octadecylsilane packings do not reliably separate all epimers; where optical purity is critical, a validated chiral derivatisation or ligand-exchange HPLC procedure is required. The relative retention time of Boc-nitro-L-arginine can shift by ±0.5 min after replacement of a nominally identical C18 column because of differences in endcapping and silica pore architecture. Calibration using a certified reference standard should therefore be repeated after each column change, and system suitability criteria should include resolution between Boc-nitro-L-arginine and free nitro-L-arginine of not less than 2.0 under the release method. Method validation for release assay should include linearity from 0.1% to 150% of the nominal test concentration, with injection repeatability expressed as relative standard deviation ≤1.0% for triplicate injections. The limit of quantitation for the deprotected impurity is commonly set at 0.10% by area; the detection limit should be no higher than 0.03% when the product is used in late-stage clinical peptide synthesis.

How Does the Nitro Guanidino Protecting Group Alter Coupling Behaviour?

In Boc SPPS, the electron-withdrawing nitro group on the guanidino side chain suppresses unwanted acylation at the ω-nitrogen but also modifies the reactivity of the activated α-carboxylate. Couplings are typically carried out at 0.1–0.4 M in a mixture of dichloromethane and N,N-dimethylformamide. The proportion of N,N-dimethylformamide is raised where the solubility of Boc-nitro-L-arginine is insufficient for homogeneous activation; typical dissolution is achieved at 0.2 M in 2:1 dichloromethane–DMF, but process batches should be filtered through a 0.45 µm PTFE in-line filter to remove insoluble particulates. Activation is generally performed with N,N’-diisopropylcarbodiimide and 1-hydroxybenzotriazole or with HBTU/6-chloro-1-hydroxybenzotriazole and N,N-diisopropylethylamine. The electron-poor nitro-guanidino system increases sensitivity to excess base; the N,N-diisopropylethylamine charge should not exceed 2.5 equiv with respect to the carboxylate, and pre-activation is held at 0–5 °C for 3–5 min before resin transfer. Incomplete coupling is monitored by Kaiser or chloranil test. If residual amino groups remain after a standard 60 min coupling cycle, a second coupling is run with 1.5 equiv amino acid and 0.5 equiv HOBt relative to initial resin substitution. Coupling progress in difficult sequences is often no longer linear after 45 min; extended reaction times beyond 120 min produce negligible gain and increase exposure of the nitro group to the base.

Automated peptide synthesizers equipped with glass reaction vessels, nitrogen sparge lines, and temperature-controlled jackets are used for repetitive Boc cycles. The main source of batch-to-batch variance at production scale is not the coupling yield but the completeness of TFA removal and neutralisation between cycles. A synthesiser programme for Boc-nitro-L-arginine commonly uses 50% trifluoroacetic acid in dichloromethane with 1–2% indole or anisole for α-amino deprotection, followed by 5% N,N-diisopropylethylamine neutralisation in DMF. Neutralisation failure leaves TFA salts on the amino terminus, reducing the next coupling efficiency by 10–20%. Residual TFA is monitored by conductivity sensors or pH paper from vessel effluent; the neutralising wash is considered complete when effluent pH remains above 7.0 for two consecutive aliquots. A production-line failure mode involving crystallisation of TFA salts in transfer lines below 18 °C is controlled by maintaining transfer-line temperature at 25 ± 2 °C.

When Boc-Nitro-L-Arginine Replaces Fmoc-Arg(Pbf)-OH in Orthogonal Synthesis

The decision to use Boc-nitro-L-arginine instead of Fmoc-Arg(Pbf)-OH is not a simple substitution of one amino acid derivative; it changes the entire protection scheme and the final cleavage unit operation. Fmoc-Arg(Pbf)-OH is processed in standard Fmoc SPPS with 20% piperidine in DMF for α-amino deprotection and final cleavage in trifluoroacetic acid/triisopropylsilane/water. Boc-nitro-L-arginine operates in Boc SPPS with trifluoroacetic acid-mediated α-amino deprotection and final guanidino liberation by hydrogenation or hydrogen fluoride/anisole. The final cleavage difference is the critical process boundary: hydrogen fluoride cleavage requires a sealed, chemically resistant reactor, typically polytetrafluoroethylene/Kel-F construction, with a calcium oxide scrubber and a vacuum-drawn HF line; catalytic hydrogenation requires pressure-rated stainless-steel or glass-lined equipment with explosion relief set to 1.5× maximum working pressure. Fmoc-Arg(Pbf)-OH is therefore preferred where standard TFA cleavage permits automated workstations and mild laboratory purification; Boc-nitro-L-arginine is chosen where the target peptide sequence is incompatible with repetitive base exposure, or where a benzyl-based resin and final hydrogenation are already required.

Comparative impurity signatures also distinguish Boc-nitro-L-arginine from Boc-Arg(Tos)-OH. The tosyl-protected analog is historically used in Boc SPPS and is cleaved under strong acid or reductive conditions, whereas the nitro-protected analog provides a different steric and electronic environment at the guanidino nitrogen, altering the solubility of the protected amino acid and the retention time of the crude peptide by roughly 1.5–3.0 min on conventional C18 gradients. The nitro compound is generally preferred when catalytic hydrogenation is already part of the deprotection scheme and when the desired peptide tolerates a reductive step; the tosyl derivative is selected when hydrogenation is undesirable because of other reducible groups. The Pbf analog, more common in Fmoc SPPS, avoids hydrogen fluoride and hydrogenation entirely, but the acid-labile Pbf cation formed during TFA cleavage requires efficient scavenger capture with thioanisole or triisopropylsilane to prevent reattachment to tryptophan residues.

At pilot scale, the handling of hydrogen fluoride is often the limiting safety constraint rather than the unit cost of the amino acid derivative. A 100 mmol peptide synthesis containing arginine may require sufficient HF to fill a 250 mL reaction vessel, but the actual charge is governed by resin swelling, scavenger ratio, and temperature control. The HF cleavage is run at −5 to 0 °C for 45–90 min; the vessel is pressurised only by the vapour pressure of HF. Overhead stirrers with magnetic or mechanical seals must be checked for compatibility because HF etches borosilicate glass and most stainless-steel alloys. p-Cresol or anisole scavenger is added at 10–15 vol% of the total cleavage cocktail to capture reactive carbocations. After evaporation of HF, the crude peptide is precipitated in cold diethyl ether, filtered through a 10–20 µm polypropylene frit, and held at −20 °C before HPLC purification. Incomplete removal of nitro protection is detected as a mass shift of +45 Da relative to the fully deprotected peptide by electrospray ionisation mass spectrometry; if this impurity exceeds 5.0%, the reduction step is repeated or the batch is reworked. Published data for this specific configuration is limited, and the operational window should be confirmed by a sequence-specific stress study.

Residual solvent is controlled by shelf-temperature and vacuum depth during final drying.

Residual solvent and water in Boc-nitro-L-arginine alter the stoichiometric ratio when the powder is weighed without correcting for volatile content. For syntheses with resin substitution above 0.5 mmol/g, the product is transferred from cold storage and equilibrated inside a desiccator over phosphorus pentoxide for 18–24 h before weighing. Vacuum drying in a tray dryer is performed at 35–40 °C and ≤1 kPa for 12 h; water content is then determined by Karl Fischer coulometry according to ISO 760:1978. If moisture exceeds 0.50%, an additional drying interval of 6 h is applied and the batch is retested. Heating above 45 °C is avoided because the tert-butoxycarbonyl group can undergo thermal elimination to form 2-methylpropene and the free α-amino degradation product; this event appears as yellowing of the powder and an increased free nitro-L-arginine peak on HPLC. The dried material is returned to sealed amber glass under argon and stored at −20 °C ± 5 °C. Repeated removal to room temperature should be minimised; each transfer cycle raises the water activity of the headspace and can increase aggregation in later peptide-resin steps.

Transport and warehousing of peptide-grade Boc-nitro-L-arginine are governed by the absence of a formal explosive or oxidiser classification. The nitro group is part of the guanidino protecting system and is not a free nitroalkane; however, the material is still segregated from reducing agents, hydrogenation catalysts, alkali metals, and concentrated aqueous ammonia. Incompatibility with hydride reducing agents, lithium aluminium hydride, and sodium amalgam is strict because these reagents reduce the nitro-guanidino moiety to byproducts that cannot be removed by simple recrystallisation. For preparative HPLC after side-chain deprotection, contact with amine-based ion-pairing agents is avoided unless the guanidino function has been fully unmasked; residual nitro-containing peptide may interact with trifluoroacetic acid in mobile phase to produce a slowly eluting peak that co-elutes with the desired product if the gradient is too shallow. Quality control of the final peptide therefore includes an in-process removal test for nitro-arginine byproduct by HPLC with a gradient slope of 0.5% organic modifier per minute and a column temperature of 30 °C. Calibration standards are prepared in 0.1% formic acid in acetonitrile–water mixtures and stored in brown glass vials at 4 °C for no more than 48 h; longer storage requires revalidation due to slow hydrolysis of the Boc group in aqueous organic media.